For those of us still following the progress of Cavatak, Merck is presenting the results of the KEYNOTE 200 trial at ESMO18 on the 20th Oct.
LBA40 - Phase 1b KEYNOTE-200. A study of an intravenously delivered oncolytic virus, Coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients
Presentation Number LBA40
Lecture Time17:15 - 17:15
Speakers Charles M. Rudin (New York, US)
http://212.114.167.162/slidecenter/esmo2018/attendee/confcal/session/calendar?q=lba40
Hi Davey,
Thanks for that .I thought they might have put it in the safe.
I made a tidy profit out of VLA and have rolled some of it into MSB.
Take a look if interested.
Aloha.